Immunotherapeutic approaches to cancer can be affected by metabolic restrictions that limit the potency of anticancer T cell responses. In this Review, DePeaux and Delgoffe discuss the metabolic features of the tumour microenvironment that limit anticancer immune responses, as well as emerging therapeutic approaches to target these.
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is now out for June 23-29, 2023
PURPOSE Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase…
Objective To describe the clinicopathological characteristics and survival outcomes of ovarian neuroendocrine neoplasms from a curated registry. Methods This is a retrospective cross-sectional study of…
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
EGFR is often found to be constitutively activated in human cancer. Dobersberger et al. develop an engineering strategy for the generation of binding domains specifically recognizing…
DAY 1 (GU Oncology)February 5, 2024 Start 6pm CET 12 noon EST6pm-6:20 (CET)12 noon-12:20 (EST)Gilberto Morgan (20 min) FDA Approvals in Oncology, OncoAlert …
The OncoAlert Newsletter is now out for June 23-29, 2023
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
